brinsupri - Search News

News

FDA, Brinsupri and Insm

Insmed wins FDA approval for future blockbuster Brinsupri

Insmed's drug Brinsupri (brensocatib) has landed a double regulatory landmark win, becoming both the first marketed dipeptidyl peptidase 1 (DPP1) inhibitor and the first therapy for non-cystic fibrosis bronchiectasis (NCFB) approved by the US Food and Drug Administration (FDA).

PharmExec · 4d

FDA Approves Insmed’s Brinsupri as First Treatment for Non-Cystic Fibrosis Bronchiectasis

· 4d · on MSN

Insmed wins FDA approval for lung disorder therapy Brinsupri

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...

Clinical Advisor2d

Brinsupri Approved for Non-Cystic Fibrosis Bronchiectasis

The Food and Drug Administration (FDA) has approved Brinsupri ™ (brensocatib) for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients aged 12 years and older.

Insmed Gets FDA OK of Brinsupri in Non-Cystic Fibrosis Bronchiectasis

Insmed has won U.S. Food and Drug Administration approval of Brinsupri as the first and only treatment for the chronic lung disease non-cystic fibrosis bronchiectasis. Insmed on Tuesday said the FDA ...

Fierce Pharma4d

Insmed’s Brinsupri scores landmark FDA nod in bronchiectasis, marking first approval of a DPP1 inhibitor

With a landmark U.S. approval Tuesday, Insmed is making waves with a new class of drug that’s also the first to be green lit in the chronic lung disease bronchiectasis. | The FDA on Tuesday signed ...

PANTHERx® Rare Selected by Insmed to Dispense BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis

PANTHERx® Rare Pharmacy, a leader in rare disease product patient access and support services in the United States, announced ...

Stocktwits on MSN3d

Hide inaccessible results